[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Cho YM, Takahashi S, Asamoto M, Suzuki S, Inaguma S, Hokaiwado N, Shirai T: Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment. Cancer Sci; 2003 Feb;94(2):153-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive tumors were limited to the anterior lobe at this time point and were found in all lobes in an age-dependent manner thereafter.
  • [MeSH-minor] Age Factors. Androgen Antagonists / administration & dosage. Androgen Antagonists / therapeutic use. Animals. Animals, Genetically Modified. Disease Progression. Drug Implants. Ethinyl Estradiol / administration & dosage. Ethinyl Estradiol / therapeutic use. Heterozygote. Ki-67 Antigen / analysis. Male. Mammary Neoplasms, Experimental / chemically induced. Mammary Neoplasms, Experimental / genetics. Neoplasm Proteins / analysis. Orchiectomy. Phenotype. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / pathology. Rats. Rats, Sprague-Dawley. Receptors, Androgen / analysis. Tongue Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • Hazardous Substances Data Bank. ETHINYLESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12708490.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminobiphenyl Compounds; 0 / Androgen Antagonists; 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Carcinogens; 0 / Drug Implants; 0 / Imidazoles; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Androgen; 0 / probasin; 13394-86-0 / 2',3-dimethyl-4-aminobiphenyl; 3XMK78S47O / Testosterone; 423D2T571U / Ethinyl Estradiol; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  •  go-up   go-down


2. Roth B, Gocht A, Metternich FU: [Cysticercosis as a rare cause of a tumor of the tongue]. Laryngorhinootologie; 2003 Aug;82(8):564-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cysticercosis as a rare cause of a tumor of the tongue].
  • This article presents the case of a 19-year-old male patient with cysticercosis in the tongue and the CNS.
  • It also presents images of histological sections of the cysticercus parasite situated in the tongue muscles and CT and MRI images of cerebral clusters.
  • In this case the patient complained about a painless, clearly delineated induration in the anterior third of the left half of the tongue.
  • Histological investigation resulted in the diagnosis of cysticercosis.
  • The patient was referred to an Institute for Tropical Medicine which confirmed the diagnosis serologically.
  • [MeSH-major] Cysticercosis / diagnosis. Tongue Diseases / diagnosis
  • [MeSH-minor] Adult. Anthelmintics / adverse effects. Anthelmintics / therapeutic use. Cerebral Cortex / pathology. Combined Modality Therapy. Diagnosis, Differential. Glossectomy. Humans. Magnetic Resonance Imaging. Male. Neurocysticercosis / diagnosis. Neurocysticercosis / drug therapy. Praziquantel / adverse effects. Praziquantel / therapeutic use. Tomography, X-Ray Computed. Tongue / pathology. Ultrasonic Therapy / instrumentation

  • Genetic Alliance. consumer health - Cysticercosis.
  • MedlinePlus Health Information. consumer health - Tongue Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12915988.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthelmintics; 6490C9U457 / Praziquantel
  •  go-up   go-down


3. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Twenty-one (68%) cases were base of tongue and 10 (32%) were tonsil.
  • RESULTS: Dose-volume constraints (V30 < 65% and V35 < 35% for anterior oral cavity and V55 < 80% and V65 < 30% for high superior pharyngeal constrictors) predictive for objective swallowing dysfunction were identified by univariate and multivariate analyses.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


Advertisement
4. Cirocco A, González F, Sáenz AM, Jiménez C, Sardi JR, Oscar RF: Embryonal rhabdomyosarcoma of the tongue. Pediatr Dermatol; 2005 May-Jun;22(3):218-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the tongue.
  • We report a 10-month-old girl who, at 4 months, developed a small, reddish, plaquelike lesion on her tongue.
  • On physical examination, there was a large, red, friable, hard in consistency, irregular tumor over the distal portion of her tongue.
  • The patient was assigned clinical stage I, group III, and began treatment according to the Intergroup Rhabdomyosarcoma Study guidelines, on triple-agent chemotherapy consisting of vincristine, actinomycin D, and cyclophosphamide.
  • After the tumor size was reduced by chemotherapy, a partial anterior glossectomy was performed.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / pathology. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916568.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down






Advertisement